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Abstract
The purpose of this study was to explore how genetic deletion and pharmacological antagonism of the
P2X7 receptor (P2rx7) alter mood-related behaviour, gene expression and stress reactivity in the brain. The
forced swim test (FST), tail suspension test (TST) and amphetamine-induced hyperlocomotion (AH) tests
were used in wild-type (P2rx7+/+) and P2rx7-deﬁcient (P2rx7x/x) mice. Biogenic amine levels were
analysed in the amygdala and striatum, adrenocorticotropic hormone (ACTH) and corticosterone levels
were measured in the plasma and pituitary after restraint stress. Chimeric mice were generated by bone
marrow transplantation. A whole genome microarray analysis with real-time polymerase chain reaction
validation was performed on the amygdala. In the absence of P2rx7s decreased behavioural despair in the
FST, reduced immobility in the TST and attenuated amphetamine-induced hyperactivity were detected.
Basal norepinephrine levels were elevated in the amygdala, whereas stress-induced ACTH and corticos-
terone responses were alleviated in P2rx7x/x mice. Sub-acute treatment with the selective P2rx7 antag-
onist, Brilliant Blue G, reproduced the eﬀect of genetic deletion in the TST and AH test in P2rx7+/+ but not
P2rx7x/xmice. No change in behavioural phenotype was observed in chimeras lacking the P2rx7 in their
haematopoietic compartment. Whole genome microarray analysis indicated a widespread up- and down-
regulation of genes crucial for synaptic function and neuroplasticity by genetic deletion. Here, we present
evidence that the absence of P2rx7s on non-haematopoietic cells leads to a mood-stabilizing phenotype in
several behavioural models and suggest a therapeutic potential of P2rx7 antagonists for the treatment of
mood disorders.
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Introduction
P2X7 receptors (P2rx7) belong to the ionotropic P2X
receptors that are sensitive to ATP and other purine
and pyrimidine nucleotides. The homo-oligomeric
P2rx7 (Surprenant et al. 1996) has distinct structural,
functional and pharmacological features within the
P2X receptor family (Jarvis & Khakh, 2009 ; Sperlagh
et al. 2006) : (1) its intracellular carboxyl-terminal do-
main is longer than those of other P2X receptor sub-
units ; (2) it has several splice variants that display
diﬀerent functionality in P2rx7+/+ and knockout mice
lines (Nicke et al. 2009) ; (3) its persistent activation
elicits the opening of a membrane pore permeable to
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high molecular weight substances ; (4) it needs high
micromolar concentrations of ATP to be activated.
P2rx7s are widely distributed in diﬀerent cells,
including cells of haematopoietic origin, neurons,
microglia and astrocytes. Accordingly, P2rx7s are in-
volved in the regulation of diﬀerent aspects of the host-
defence reaction (Chen & Brosnan, 2006 ; di Virgilio
et al. 2009). A major immunomodulatory function
of P2rx7 activation is that it acts as a necessary co-
stimulus for the post-translational processing and
subsequent release of the pro-inﬂammatory cytokine
interleukin (IL)-1b in peripheral immune cells in re-
sponse to bacterial endotoxin (Ferrari et al. 2006;
Solle et al. 2001).
The primary role of P2rx7s in the brain is the
modulation of neurotransmitter release (Anderson &
Nedergaard, 2006; Sperlagh et al. 2006, 2007a). The
activation of P2rx7s elicits Ca2+ inﬂux (Miras-Portugal
et al. 2003), followed by increased glutamate and sub-
sequent c-aminobutyric acid (GABA) release (Alloisio
et al. 2008; Papp et al. 2004; Patti et al. 2006; Sperlagh
et al. 2002). By regulating the activation and prolifer-
ation of microglia and the subsequent pathological
process leading to neuronal death (Monif et al. 2009;
Skaper et al. 2006), P2rx7s might also act as a ‘danger
signal’ and contribute to neurodegenerative and
neuroplasticity events underlying a variety of central
nervous system disorders from Alzheimer’s disease to
mood disorders (Burnstock, 2008 ; Skaper et al. 2010;
Sperlagh et al. 2006).
Gene polymorphism studies have revealed that
non-synonymous single nucleotide polymorphisms in
the human P2X7 gene (P2RX7) aﬀect receptor function
(Roger et al. 2010; Stokes et al. 2010) and are associated
with bipolar disorder (Barden et al. 2006; Hejjas et al.
2009; McQuillin et al. 2009; Nagy et al. 2008; Soronen
et al. 2011) and major depressive disorder (Lucae et al.
2006; Soronen et al. 2011; but see Green et al. 2009;
Grigoroiu-Serbanescu et al. 2010; Lavebratt et al. 2010;
Viikki et al. 2011). These mutations might underlie the
susceptibility to genetically related mood disorders
(Harvey et al. 2007; Sluyter et al. 2010). Moreover, re-
cent studies found an antidepressant phenotype in
mice genetically deﬁcient in P2rx7s (Basso et al. 2009;
Boucher et al. 2011). Nevertheless, it is not known, how
P2rx7 aﬀects mania-like behaviour and whether be-
havioural alterations detected in the absence of P2rx7s
can be reproduced by pharmacological blockade. In
addition, the mechanism, whereby the activity of
P2rx7 leads to alterations in mood also remains to be
explored.
We report here that, in addition to the known anti-
depressant-like eﬀect, the genetic deletion of P2rx7
(P2rx7x/x) results in a mood stabilizing-like pheno-
type and P2rx7 antagonists reproduce these behav-
ioural changes. The lack of P2rx7s also leads to
decreased stress response to restraint stress and
region-speciﬁc alterations in brain monoamine levels,
in particular in the amygdala, an intrinsic part of
the limbic system. Experiments performed on bone
marrow chimeric mice demonstrated that behavioural
alterations detected in P2rx7x/x mice are not related
to P2rx7s on haematopoietic cells. Therefore, a whole
genome microarray analysis was performed in the
amygdala, which revealed widespread alterations in
the expression of genes responsible for synaptic sig-
nalling and neuroplasticity, in the absence of P2rx7s.
Method
Animals
All studies were conducted in accordance with the
principles and procedures outlined in the NIH Guide
for the Care and Use of Laboratory Animals and
were approved by the local Animal Care Committee
of the IEM HAS. This study used 2- to 3-month old
(approx. 30 g), drug- and test-naive male wild-type
(P2rx7+/+) and knockoutmice (P2rx7x/x), whichwere
housed in a light-controlled (12-h light/dark cycle ;
lights on 07:00 hours), humidity-controlled (60¡10%)
and temperature-controlled (23¡2 xC) roomwith food
and water available ad libitum. Homozygous P2rx7+/+
mice were bred on a background of C57BL/6J. The
original breeding pairs of P2rx7x/x mice (C57BL/6J-
based) were kindly supplied by Christopher Gabel
(Pﬁzer Inc., USA). The animals contained the DNA
construct [P2X7-F1 (5k-CGGCGTGCGTTTTGACATC-
CT-3k) and P2X7-R2 (5k-AGGGCCCTGCGGTTCTC-
3k)], previously shown to produce the genetic deletion
of P2rx7 (Solle et al. 2001). Oﬀspring of this mouse line
were cross-bred with P2rx7+/+mice and the resulting
heterozygotes were used as breeding stock for the
F1 generation oﬀspring employed in the behaviour
studies. The genotypes of animals were conﬁrmed
by polymerase chain reaction (PCR) analysis, as de-
scribed previously (Solle et al. 2001). Mice carrying the
CD45.1 allele on the C57BL/6J genetic background
were obtained from the Jackson Laboratory (USA).
Behaviour experiments
Mice establish strong dominance hierarchies in both
their natural habitats and the laboratory (Capanna et al.
1984; Ferrari et al. 1998; Poshivalov 1980). Therefore,
to avoid confounds from social status, subjects were
kept in individual cages (15r45r20 cm) for 1 wk
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before experimentation. In contrast to rats, isolation
does not increase but slightly decreases depression-
like behaviour in mice, at least in the Swiss strain of
this species (Hilakivi et al. 1989).
All experiments and treatments were carried out
during the light phase (07:00–19:00 hours). P2rx7+/+
and P2rx7x/x mice were submitted to testing in
alternation. Except for the elevated plus maze (EPM)
test, which immediately followed the open ﬁeld (OF)
test, the animals used in this study were subjected to
behaviour tests only once. Treatments with the P2rx7
antagonist, Brilliant Blue G (BBG; Sigma-Aldrich,
Hungary) or the selective serotonin reuptake inhibitor,
citalopram (Sigma-Aldrich), were applied i.p. 30 min
before testing. The doses were chosen based on litera-
ture data (Diaz-Hernandez et al. 2009) and preliminary
tests.
In the forced swim test (FST), the OF test and the
EPM test, behaviour was video-recorded and analysed
later with a computer-based event recorder by an ex-
perimenter blind to the genotype.
Forced swim test
Behavioural despair was analysed as described pre-
viously (Porsolt et al. 1977). Each mouse was placed
in a transparent glass cylinder ﬁlled with water
(22¡0.5 xC) and submitted to 15 min of forced swim,
divided into three equal trial periods (5 min each) and
followed by a single 5-min test period the next day.
Fresh water was used for each mouse and four ani-
mals were tested simultaneously. After the test period,
the mice were removed from the cylinder, dried with
paper towels and a clean towel was left in the home
cage for 1 h to avoid cooling. The time of immobility
(ﬂoating) was expressed in seconds.
Automated tail suspension test (TST)
This test was performed using an automated tail
suspension device (BIO-TST2, Bioseb, France), follow-
ing the method described in Cryan et al. (2005), which
was connected to a computer that recorded the activity
of the animals during test sessions. Three mice were
individually suspended by the tail onto the hooks of
the device using adhesive tape (distance from tip of
tail was 1–2 cm). The automatic measurements were
started within 5–10 s after placing the last animal into
the chamber and each measurement lasted 6 min.
During the test, the animals showed several escaping
behaviours with temporary periods of immobility. The
threshold was set at level 6. The time of immobility
was expressed in seconds. In accordance with the ob-
servations of Mayorga & Lucki (2001), a proportion of
the animals (8.9% on average, 0–16%, depending on
the experiment) displayed tail-climbing behaviour.
The data of these animals were post-hoc excluded from
the calculations.
OF test and EPM test
For technical details, see Supplement 1 (available
online).
Amphetamine-induced hyperlocomotion (AH) in the
OF test
Experiments were performed in the light phase under
dimmed lights (y3 lx). At least 3 d before the tests,
animals were transferred to the experimental room.
Each animal was placed in the centre of a non-
transparent Plexiglas arena (dimensions : 40r40r
40 cm) for a habituation period of 30 min and then re-
moved for 2 min into their home cages for i.p. saline or
D-amphetamine-sulfate (equivalent to 2.5 mg/kg free
base, A5880; Sigma-Aldrich, Hungary) treatment.
Immediately after amphetamine (or saline) injection,
each mouse was placed back into the box and the
locomotor activity of the animals was recorded for
90 min using a video camera positioned above the
arena. To measure locomotor activity, video ﬁles were
analysed oﬄine by converting them into single frames
(25 frames/s) and a custom-written motion tracking
algorithm was applied within the image processing
software ImageJ. The total distance (m) was provided
for the 90 min of the experiment. Hyperactivity in-
duced by amphetamine was expressed in percentage
of locomotor activity measured in saline-treated mice
under an identical period.
IL-1b experiments
All animals were given an i.p. injection of sterile
saline (0.9% NaCl) or bacterial lipopolysaccharide
(LPS, 250 mg/kg i.p.) with an injection volume of
0.1 ml/mouse). Animals were killed by decapitation
6 h after LPS injection. The amygdalae were collected,
frozen on dry ice and stored at x70 xC until further
investigation. The IL-1b assays were performed as
described previously (Cso¨lle & Sperla´gh, 2010).
High performance liquid chromatography (HPLC)
analysis of endogenous biogenic amine levels
After various treatments (saline/2.5 mg/kg amphet-
amine i.p. ; 30 min restraint ; saline/50 mg/kg.d BBG
i.p. for 7 d), animals were killed by decapitation
and native amygdalae and striata were frozen in
liquid nitrogen. The weighted frozen tissue was
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homogenized in ice-cold 0.1 M perchloric acid con-
taining theophylline (10 mM; internal standard) and
0.5 mM sodium metabisulphite. The suspension was
centrifuged at 300 g for 10 min at 4 xC. The perchloric
anion was precipitated by addition of 1 M KOH,
removed by centrifugation and the protein content
of the pellet was determined according to the method
of Lowry et al. (1951). The supernatant was kept
at x20 xC until analysis. Biogenic amines were meas-
ured by a liquid–liquid, two-dimensional reversed
phase and ion pair-reversed phase chromatographic
separation, as described earlier (Baranyi et al. 2006)
using a Gilson liquid chromatographic system (Gilson
Medical Electronics Inc., USA) equipped with an
Applied Biosystems 785/A UV and BAS CC-4 am-
perometric detector in a cascade line. Data were ex-
pressed as pmol per mg protein.
[3H]Dopamine release experiments
[3H]Dopamine release experiments on acute striatal
slices were performed according to the method de-
scribed in Milusheva et al. (2010). For the detailed
protocol of release experiments, see Supplement 2.
Stress studies
Restraint stress consisted of placing mice for 30 min in
ventilated polyethylene tubes (inner diameter : 2.5 cm;
length: 10 cm), closed with plastic tape (Lolait et al.
2007), and was immediately (within 15 s) followed by
decapitation. Controls were decapitated at the same
time under basal conditions. Trunk blood was col-
lected in ice-cold sodium-EDTA (20%) during the light
phase between 09:00 and 13:00 hours and centrifuged
at 3000 g for 20 min at x4 xC. The plasma was stored
at x20 xC until the hormone assays were performed.
The pituitaries were dissected into four pieces and in-
cubated at 37 xC in 1 ml Dulbecco’s minimal essential
medium (DMEM, pH 7.4 ; Sigma) containing 2.5%
bovine serum albumin in a 95% O2/5% CO2 atmos-
phere (one gland/tube) for 60 min. After a further
pre-incubation with fresh DMEM for 60 min, 15 min
samples were collected three times with corticotropin-
releasing hormone (CRH)-containing (5r10x8 M;
Sigma) medium in the second fraction.
Hormone assays
Adrenocorticotropic hormone (ACTH) and cortico-
sterone in the trunk blood and in acutely isolated
pituitaries were measured by radioimmunoassay in
50-ml unextracted samples as described previously
(Zelena et al. 2008).
Bone marrow chimeras
Bone marrow chimeras were generated by transplan-
tation of P2rx7+/+ or P2rx7x/x bone marrow cells
(carrying the CD45.2 allele) into lethally irradiated
recipients carrying the CD45.1 allele as described
previously (Jakus et al. 2009). The repopulation of the
peripheral leukocyte compartment by donor-derived
cells was tested 8 wk after transplantation by ﬂow
cytometric analysis of blood samples stained for
the granulocyte-speciﬁc Gr1 and the donor-speciﬁc
CD45.2 markers (Jakus et al. 2009). Percent repopu-
lation was deﬁned as the percentage of CD45.2-
positive cells among Gr1-positive cells with typical
forward and side-scatter characteristics.
Preparation of microglia
Microglia was prepared following the method de-
scribed by Racz et al. (2008), with slight modiﬁcations.
Brieﬂy, single-cell suspensions frommouse brain were
generated using a commercially available enzymatic
kit (Miltenyi Neural Tissue Dissociation kit ‘P’ ;
Miltenyi Biotec, Germany) and ﬁltered through an 83-
mm sieve. Percoll (GE Healthcare, UK) gradients of 75/
25% were performed for fractionation of cells at 800 g
for 25 min and 800 g for 10 min and brain mono-
nuclear cells were collected from the interface.
Immunohistochemistry
Light and eletronmicrosopic immunostaining for
P2rx7s and the microglia marker CD11b was per-
formed using standard protocols described earlier
(Cso¨lle et al. 2008). For the detailed protocol of im-
munohistochemistry, see Supplement 3.
Microarray experiments and real-time PCR
validation
Mice were randomly assigned to experimental groups
and injected i.p. with sterile saline (0.9% NaCl)
or LPS (250 mg/kg) and killed by decapitation 6 h
after injection. Microarray proﬁling on amygdala
samples was performed in the Agilent Microarray
Core Facility (Semmelweis University, Budapest ;
http://www.dgci.sote.hu/microarray). The complete
microarray expression data are deposited at NCBI’s
Gene Expression Omnibus (Edgar et al. 2002) through
GEO series accession number GSE21218 (http://
www.ncbi.nlm.nih.gov/geo/query/acc.cgi?token=
rzwxlikqskwayfk&acc=GSE21218). The microarray
data were further analysed using the bioinformatics
analysis tool GeneCodis (Carmona-Saez et al. 2007;
Nogales-Cadenas et al. 2009).
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Real-time PCR validation
TaqMan low-density arrays (TLDA microﬂuidic card;
Applied Biosystems, USA) were performed on 92
selected genes of interest and four housekeeping genes
(18S rRNA, Gapdh, Hprt, B2m) (Vandesompele et al.
2002).
See Supplement 4 for the technical details of the
microarray and real-time PCR experiments.
Statistics
All data shown are the means¡S.E.M. of n determi-
nations. OF and EPM data were evaluated by analysis
of variance (ANOVA). TST and AH data were ana-
lysed by one-way ANOVA followed by Dunnett’s test.
Hormone levels, monoamine contents, IL-1b, micro-
array and PCR data were analysed by two-way
ANOVA. The FST and in vitro ACTH secretion was
analysed by repeated measures ANOVA. The
Student’s t test and Fischer’s LSD test were used for
pairwise comparisons. Unless otherwise stated, stat-
istical analyses were performed using the Statistica
program (Statsoft, USA). The level of signiﬁcance was
set at p<0.05.
Results
Genetic deletion of P2rx7 leads to mood-stabilizing
behavioural phenotype
To model depressive-like behaviour, occurring during
major depressive disorder and the depressive pole of
bipolar disorder, FST and TST were used. In the FST,
we have used the widely used behavioural despair
paradigm, originally described by Porsolt et al. (1977),
which involves subjects being forced to swim twice
on two consecutive days. P2rx7+/+ mice displayed a
time-dependent increase in the time of immobility
during consecutive 5-min periods of the ﬁrst trial,
indicating that they developed behavioural despair,
a well-known depressive-like behaviour (Fig. 1a).
P2rx7x/xmice were less prone to develop depression-
like behaviour than P2rx7+/+ mice (Fig. 1a). During
the ﬁrst trial, the duration of immobility was similar
in the two genotypes (92.43¡21.12 s, for wild-type
vs. 118.38¡16.46 s for P2rx7x/x ; genotype: F1,18=
0.05, p<0.8). In P2rx7+/+mice, the time spent in im-
mobility increased over time during the ﬁrst trial
(F3,36=3.61, p<0.02). In P2rx7x/x mice, parallel chan-
ges were seen, but these were not signiﬁcant
(F3,36=0.30, p>0.8). When the two genotypes were
considered together, the timergenotype interaction
was signiﬁcant (F3,54=2.92, p<0.04) and signiﬁcant
time-related changes were seen in P2rx7+/+ mice
only.
The basal time of immobility in the TST was
167.90¡17.13 s (n=9) in P2rx7+/+ mice (Fig. 1b). In
line with previous data (Basso et al. 2009), P2rx7x/x
mice spent signiﬁcantly less time with immobility (i.e.
they exhibited antidepressant-like phenotype in this
test as well ; 110.24¡15.84 s, n=11, p<0.05, Fig. 1b).
Neither basal locomotor activity nor anxiety-like
behaviour, examined in the OF and EPM tests, was
aﬀected by the genetic disruption of the P2rx7 gene
(Supplementary Fig. 1a, b).
As a behavioural model of manic pole of bipolar
disorder (Einat, 2007), the AH test was used in our
study. The locomotor activity of saline-treated mice,
expressed as the total covered distance during the test
period, was similar in P2rx7+/+ and P2rx7x/x mice
(120.17¡24.71 m, n=9 and 156.53¡18.48 m, n=10,
respectively, p>0.05). By contrast, amphetamine
(2.5 mg/kg i.p.) induced hyperactivity was signiﬁ-
cantly attenuated in mice genetically deﬁcient in P2rx7
(Fig. 1c).
Neurochemical changes and stress-induced hormone
response in the absence of P2rx7
The level of IL-1b 6 h after saline administration was
6.06¡1.18 pg/ml in the amygdalae of P2rx7+/+ mice
(Fig. 1d, n=4). Systemic LPS administration (250 mg/
kg i.p.) caused a signiﬁcant elevation in IL-1b levels
(83.94¡3.01 pg/ml, n=8, F1,28=45.2, p<0.001, Fig.
1d). The IL-1b level in the amygdalae of saline-treated
P2rx7x/x mice was 5.29¡1.48 pg/ml (n=4), not sig-
niﬁcantly diﬀerent from P2rx7+/+ mice (p>0.05, Fig.
1d). The LPS-induced elevation of IL-1b level was
signiﬁcantly attenuated in the amygdalae of P2rx7x/x
mice (32.53¡1.55 pg/ml, n=8 ; genotype: F1,28=183.3,
p<0.001 ; interaction : F1,28=42.55, p<0.001, Fig. 1d).
To explore neurochemical correlates of changes in
behaviour, the level of norepinephrine, dopamine and
serotonin (5-HT) was also analysed in the amygdala
and striatum of saline and amphetamine (2.5 mg/kg
i.p.) treated P2rx7+/+ and P2rx7x/x mice. The basal
level of norepinephrine was elevated in the absence of
P2rx7 in the amygdala (genotype: F1,27=3.30, p=0.08 ;
interaction : F1,27=6.52, p=0.016; post-hoc comparison
by Fischer’s LSD test, p<0.005), whereas no change in
basal norepinephrine level was found in the striatum
(29.37¡13.79, n=7 and 18.21¡3.83 pmol/mg protein,
n=8 in P2rx7+/+ and P2rx7x/x mice, respectively ;
interaction : F1,27=0.05, p>0.8). Likewise, basal dopa-
mine and 5-HT levels were not aﬀected by the
genetic deletion either in the amygdala (Fig. 2a–c,
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dopamine: F1,27=0.05, p>0.8 ; 5-HT: F1,27=1.07,
p>0.3) or in the striatum of saline-treated mice (Fig. 2d
and data not shown). Consistent with the observed
increase in locomotor activity, amphetamine treatment
caused an elevation in the dopamine content of the
striatum of P2rx7+/+ mice (Fig. 2d, F1,27=10.08 ;
p<0.004), a reduction of norepinephrine level in the
amygdala (F1,27=17.17, p<0.001), without changing
the 5-HT and dopamine levels in the amygdala
(Fig. 2a–c, 5-HT: F1,27=0.23 ; p>0.6, dopamine:
F1,27=0.43, p>0.5) and with a tendency for lower
norepinephrine levels in the striatum (26.4¡3.23, n=7
and 12.2¡3.07 pmol/mg protein, n=8 in P2rx7+/+
and P2rx7x/x mice, respectively ; genotype: F1,27=
3.36, p=0.07). In line with these ﬁndings, when acute
striatal slices treated in vitro with amphetamine
(30 mM), a profound increase in [3H]dopamine eﬄux
was observed (Fig. 2e). Both the amphetamine-
induced increase in dopamine content (Fig. 2d ; inter-
action : F1,27=2.91, p=0.09, post-hoc comparison by
Fischer’s LSD test : p<0.001) and [3H]dopamine eﬄux
(Fig. 2e) were signiﬁcantly attenuated in P2rx7x/x
mice, without the alteration of basal and electrical ﬁeld
stimulation-evoked [3H]dopamine release (Fig. 2e).
Body, thymus and adrenal gland weights remained
unchanged by P2rx7 gene disruption (Supplementary
Table S1). Similarly, resting ACTH and corticosterone
levels were not aﬀected by genotype (Fig. 3a, b ;
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Fig. 1. Genetic deletion of P2rx7s in mice leads to an antidepressant-like phenotype in the forced swim test (FST) and tail
suspension test (TST) and mood stabilizing-like phenotype in amphetamine-induced hyperlocomotion test (AH), but does not
aﬀect basal interleukin (IL)-1b levels in the amygdala. (a) P2rx7x/xmice failed to develop the depression-like behaviour typical
to the FST. The time of immobility is expressed in seconds. * Indicates signiﬁcant changes from immobility values observed
during min 0–5 of the ﬁrst day, n=20/group; * p<0.05. (b) Genetic disruption decreased basal immobility in the TST
(n=9–11, * p<0.05 vs. P2rx7+/+, Student’s t test). The immobility time is expressed in seconds. The total test period was 360 s.
(c) Amphetamine-induced hyperactivity is signiﬁcantly attenuated in P2rx7x/x mice. Mice were placed into the open ﬁeld
arena for a 30-min habituation period and then injected with i.p. saline (Sal) or D-amphetamine-sulfate (2.5 mg/kg). Locomotor
activity was assessed for 90 min immediately after the injection and expressed as the percentage of Sal-treated mice, n=9–10,
*** p<0.001 vs. P2rx7+/+, Student’s t test. Drug- and test-naive male homozygous mice (P2rx7+/+ and P2rx7x/x, aged
2–3 months) weighing approximately 30 g were used in the experiments. (d) IL-1b protein level in the amygdala of P2rx7+/+
and P2rx7x/x mice after Sal and lipopolysaccharide (LPS) treatment. The IL-1b protein level was similar in the amygdalae of
Sal-treated P2rx7+/+ and P2rx7x/xmice. Injection of LPS (E. coli ; 250 mg/kg i.p.) signiﬁcantly increased the level of IL-1b in the
amygdalae of P2rx7+/+ mice 6 h after treatment. IL-1b protein level was less elevated in the amygdalae of P2rx7x/x mice in
response to systemic endotoxin. The levels of IL-1b were quantiﬁed in the supernatants by ELISA. Data are given as the mean
level of cytokines¡S.E.M., expressed in pg/ml. * Indicates signiﬁcant diﬀerences between Sal- and LPS-treated and between
P2rx7+/+ and P2rx7x/x mice (n=4 per group, *** p<0.001, two-way analysis of variance).
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ACTH: F1,34=0.1, p>0.9 ; corticosterone : F1,33=1.06,
p>0.3). Restraint stress increased the level of both
hormones (ACTH: F1,34=6.9, p=0.013 ; corticosterone :
F1,33=272.7, p<0.001), but the elevation of ACTH
levels reached the level of signiﬁcance in P2rx7+/+
animals only (p=0.03 ; Fig. 3a). In addition, the corti-
costerone increase was signiﬁcantly lower in P2rx7x/x
mice, than in P2rx7+/+ mice (p=0.048; Fig. 3b). In
isolated in vitro pituitaries, CRH treatment signiﬁ-
cantly increased ACTH secretion (Fig. 3c). However,
Amygdala
0
5
10
15
20
25
30
D
A
 (p
m
ol
/m
g 
pr
ot
ei
n)
Amygdala
0
5
10
15
20
25
30
35
5-
H
T 
(p
m
ol
/m
g 
pr
ot
ei
n)
Striatum
0
500
1000
1500
2000
2500
3000
D
A
 (p
m
ol
/m
g 
pr
ot
ei
n)
***
**
(a) (b)
(c)
(e)
(d)
Amygdala
0
10
20
30
40
50
P2rx7+/+ P2rx7–/– P2rx7+/+ P2rx7–/–
P2rx7+/+ P2rx7–/–P2rx7+/+ P2rx7–/–
N
E 
(p
m
ol
/m
g 
pr
ot
ei
n)
Sal
Amph
***
***
Sal
Amph
Sal
Amph
Sal
Amph
Striatum
0
1
2
3
4
5
6
7
8
0 6 12 18 24 30 36 42 48 54 60 min
[3
H
]d
op
am
in
e 
(%
) **
Amph
EFS1 EFS2
*
P2rx7+/+
P2rx7–/–
Fig. 2. Changes in the content of norepinephrine (NE) (a), dopamine (DA) (b), 5-HT (c) in the amygdala ; dopamine content in
the striatum (d) and release of [3H]dopamine (e) in acute striatal slices in the absence of P2rx7. (a–d) P2rx7+/+ and P2rx7x/xmice
were treated with saline (Sal) or amphetamine (Amph, 2.5 mg/kg i.p.) and 30 min after the treatment were decapitated. NE,
DA and 5-HT levels were analysed by high performance liquid chromatography in the amygdala and striatum and are
expressed in pmol/mg protein. * Indicates signiﬁcant diﬀerences between P2rx7+/+ and P2rx7x/x mice and between Sal- and
Amph-treated groups, as indicated (n=7–8/group, ** p<0.01, *** p<0.001, two-way analysis of variance followed by Fischer’s
LSD test). (e) Basal, electrical ﬁeld stimulation (EFS)- and Amph-induced [3H]dopamine eﬄux from striatal slices of P2rx7+/+
and P2rx7x/x mice. Striatal slices were incubated with [3H]dopamine and superfused with Krebs’ solution. EFS (20 V, 2 Hz,
240 shocks) and Amph (30 mM) were applied as indicated by the horizontal bars. The eﬄux of [3H]dopamine is expressed
as fractional release, which represents the tritium content in a sample as a percentage of the actual total tritium content.
Amph-induced [3H]dopamine release was signiﬁcantly decreased in striatal slices of P2rx7x/xmice, whereas basal and electrical
stimulation-induced eﬄux remained unchanged. n=8/group, * p<0.05, ** p<0.01, Student’s t test.
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this eﬀect depended on genotype (F1,17=4.65, p=
0.045), with a signiﬁcantly smaller response in P2rx7x/x
mice (Fig. 3c). After restraint stress, norepinephrine,
dopamine and 5-HT levels were all elevated in
the amygdala of P2rx7x/x mice when compared to
P2rx7+/+littermates (Fig. 3d).
P2rx7 antagonist treatment reproduces the eﬀect
of genetic deletion
Next, we asked whether the behavioural phenotype
detected in P2rx7x/xmice could be reproduced by the
systemic administration of a P2rx7 antagonist. BBG, a
selective P2rx7 antagonist, was ineﬀective upon acute
application (50 mg/kg i.p.), but it dose-dependently
(25–50 mg/kg i.p.) inhibited depressive-like behav-
iour after a 1-wk sub-acute treatment in the TST
(Fig. 4a, b). Citalopram (acute treatment, 15 mg/kg
i.p.), which was used as a reference compound, eli-
cited a 40.6% decrease in the immobility time in the
TST in P2rx7+/+ mice (Fig. 4c). Sub-acute (Fig. 4d),
but not acute (data not shown) BBG treatment
(25–50 mg/kg i.p.) also reproduced the eﬀect of genetic
deletion in the AH test and elevated norepinephrine
levels in the amygdala (Fig. 4g). When sub-acute BBG
treatment was applied in P2rx7x/x mice, no signiﬁ-
cant change either in immobility in the TST (Fig. 4e) or
in AH (Fig. 4 f) was detected.
Alteration of behavioural phenotype of P2rx7x/x
mice is not related to P2rx7s expressed on cells of
haematopoietic origin
To test whether the alteration of behavioural pheno-
type detected in P2rx7x/x mice was due to the lack of
P2rx7s on cells of haematopoietic origin, we generated
bone marrow chimeras that lacked the P2rx7 only in
their haematopoietic compartment (Fig. 5a). Bone
marrow cells harvested from P2rx7+/+ or P2rx7x/x
mice (expressing the CD45.2 leukocyte marker) were
injected i.v. into lethally irradiated congenic recipients
carrying the CD45.1 marker. The eﬃciency of the re-
constitution was tested 8 wk after transplantation
by ﬂow cytometric analysis of the expression of the
donor-speciﬁc CD45.2 marker in peripheral blood
leukocytes. As shown in Fig. 5b, CD45.2 was present
on granulocytes of the donor strain but not on those of
the recipient strain. Importantly, granulocytes isolated
from bone marrow chimeras used for the behavioural
studies, engrafted with either P2rx7+/+ or P2rx7x/x
bone marrow cells, were practically exclusively
(>99%) of donor (CD45.2-positive) origin. The re-
cruitment of donor-derived cells was also assessed by
immunocytochemical staining of P2rx7s in microglia
cells isolated from the brains of intact mice and bone
marrow chimeras. As shown by ﬂuorescent and elec-
tron microscopic images, the cell membranes of
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Fig. 3. P2rx7x/xmice [grey bars in (a) and (b)] respond with a
decreased elevation of adrenocorticotropic hormone (ACTH)
and corticosterone in the plasma (a, b) and pituitary (c) and
increased norepinephrine (NE) level (d) in the amygdala to
stress. Hormonal secretion was evaluated after 30 min of
restraint. Plasma levels of ACTH (a) and corticosterone
(b) were measured by radioimmunoassay of trunk blood
(n=9–10). The resting ACTH and corticosterone levels were
not aﬀected by genotype. Restraint signiﬁcantly increased the
level of both hormones, but the elevation of ACTH levels
reached the level of signiﬁcance in P2rx7+/+ animals (clear
bars) only (p=0.03). (c) The ACTH response to 5r10x8 M
corticotropin-releasing hormone (CRH) was studied in vitro
(n=10 per group). Fifteen-min fractions were collected. CRH
treatment signiﬁcantly increased ACTH secretion. This eﬀect
was dependent on the genotype and there was a signiﬁcantly
smaller response in P2rx7x/x mice. C, control ; Res, exposed
to 30-min restraint. Post-hoc comparisons : * p<0.05 ; ** p<0.01
vs. control ; # p<0.05 vs. P2rx7+/+. (d) The level of NE,
dopamine (DA) and 5-HT was analysed by high performance
liquid chromatography in the amygdalae of P2rx7+/+ and
P2rx7x/x mice after 30 min restraint. The results are
expressed as pmol/mg protein. * Represents a signiﬁcant
diﬀerence between P2rx7+/+ and P2rx7x/x animals,
n=10–12/group, * p<0.05, ** p<0.01, Student’s t test.
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microglia (i.e. cells positive for the microglia marker
CD11b) of intact P2rx7+/+ mice and of bone marrow
chimeras engrafted with P2rx7+/+ bone marrow cells
(CD45.1/P2rx7+/+) showed intense P2rx7 im-
munoreactivity (Fig. 5c, e). Because not all microglia
are positive for CD11b and not only microglia express
the P2rx7, CD11b-negative/P2rx7-positive and
CD11b-positive/P2rx7-negative cells were also found
in the preparation. In contrast, no P2rx7 immuno-
reactivity was observed on microglial cells isolated
from intact P2rx7x/x mice (Fig. 5d). Microglia cells of
bone marrow chimeras engrafted with P2rx7x/x bone
marrow cells (CD45.1/P2rx7x/x) also displayed
scarce P2rx7 immunoreactivity, whereas other non-
haematopoietic cells of the preparation were stained
with the antibody against the P2rx7 (Fig. 5 f). Bone
marrow chimeric mice were subjected to the TST
and AH as described above. No diﬀerence was found
in the time of immobility in either the TST (Fig. 5g) or
in the hyperlocomotion in the AH (Fig. 5h), showing
that the mood stabilizing-like phenotype found
in P2rx7x/x mice was not transferred to P2rx7+/+ re-
cipients with the engraftment of the P2rx7x/x bone
marrow cells.
Alteration of the gene expression proﬁle in the
amygdalae of P2rx7x/x mice
Because previous experiments and literature data in-
dicated that monoamine transmitter levels and c-Fos
expression (Boucher et al. 2011) are regulated by P2rx7
in the amygdala, we next examined how global gene
expression is changed in the absence of P2rx7 in this
region and LPS treatment was used as a reference
stimulus. Four amygdala samples/group collected
from P2rx7+/+ and P2rx7x/x mice 6 h after LPS
(250 mg/kg i.p.) or saline treatment were subjected to
whole genome microarray analysis. Out of the 41041
transcripts printed on the microarrays, the expression
of a total of 8739 transcripts was signiﬁcantly altered
with the applied statistical ﬁlters (>2.0-fold change;
p<0.05 ; Benjamini–Hochberg’s multiple correction ;
Fig. 6a). These transcripts were sorted according to
their main eﬀect, namely, genotype and treatment, as
illustrated in the Venn diagram in Fig. 6a. Deﬁciency
of P2rx7 had the most profound eﬀect on the ex-
pression proﬁle, changing the expression of 8448
transcripts (3133 increased, 5315 decreased, Fig. 6b)
independently from the treatment, followed by the
eﬀect of LPS, which aﬀected the expression of 570
transcripts, (415 increased, 155 decreased) indepen-
dently from the genotype. Four transcripts, as illus-
trated by the red/blue/green intersection in the Venn
diagram, were diﬀerentially altered by the treatment,
depending on the genotype.
To further understand the functional impact of the
biological processes aﬀected by P2rx7 deﬁciency,
microarray data were further subjected to gene on-
tology analysis. Because the total number of modiﬁed
genes aﬀected only by P2rx7 deletion (8165) was rela-
tively large, 588 genes showing the top rank of up- and
down-regulation were selected for gene ontology
analysis by GeneCodis (Supplementary Table S2a).
This allowed us to investigate the association of the
588 genes using the deﬁned algorithm to determine
biological annotations or combinations of annotations
that were over-represented with regard to a reference
list of Mus musculus deposited in the NCBI GenBank
database. The GeneCodis analysis generated a re-
lationship of 373 annotation groups characterized with
the Gene Ontology (GO) Biological Process, including
transport, ion transport, signal transduction, synaptic
transmission, G-protein coupled receptor protein
signalling pathway, ATP synthesis coupled proton
transport, transcription, regulation of transcription
and GABA signalling pathway (Supplementary Table
S2b, c). The genes involved in each annotation group
are listed in Supplementary Table S2 with reference
to their involved GO categories. The annotation
groups were further sorted using a permutation test
for p value correction.
Using the data generated by the GO analyses and
searching biological plausibility for depression (e.g.
synaptic transmission and neuroplasticity), we chose
60 genes for further validation out of the 8165 tran-
scripts that were changed signiﬁcantly by P2rx7 de-
ﬁciency, regardless of the eﬀect of LPS treatment, and
showed a fold change (FC) of o2.0 (Table 1). Among
the 287 transcripts that had a signiﬁcant LPS treatment
eﬀect, regardless of the eﬀect of genotype, 17 tran-
scripts were selected that had biological plausibility in
inﬂammatory and immune responses (Table 2).
Microarray experiments were validated by asses-
sing the expression of genes of interest using quanti-
tative TLDA real-time PCR, applying both sample
and treatment validation. Signiﬁcant down- or up-
regulatory eﬀects of P2rx7 deﬁciency were conﬁrmed
for 29 genes (Table 1a, b), which corresponded to
48% of the total genes tested by real-time PCR.
Among these genes, 25 genes were down-regulated in
P2rx7x/x mice, including genes encoding various
subunits of the GABAA receptor (Gabrb2, Gabrb3,
Gabrg2, Gabrg3), ionotropic glutamate receptors
(AMPA2, AMPA4), the metabotropic glutamate re-
ceptor 7 (Grm7), the a2 adrenergic receptor (Adra2a),
the CB1 cannabinoid receptor (Cnr1), the D2 dopamine
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Fig. 4. The selective P2rx7 antagonist Brilliant Blue G (BBG) exhibits antidepressant-like activity in the tail suspension test (TST),
decreases amphetamine-induced hyperactivity and elevates norepinephrine (NE) level in the amygdala in P2rx7+/+, but not
P2rx7x/x mice. (a) The eﬀect of acute BBG treatment on basal immobility in P2rx7+/+ mice (n=13–15). (b) Eﬀect of sub-acute,
1-wk treatment with BBG on basal immobility in P2rx7+/+ mice. Mice were treated with BBG for 7 d with the daily doses
indicated on the abscissa or with saline (Sal) and then submitted to the TST (n=13–15, * p<0.05 vs. SAL, one-way analysis of
variance (ANOVA), followed by Dunnett’s test). (c) Citalopram (Cit ; 15 mg/kg), the potent selective serotonin reuptake inhibitor
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receptor (Drd2), dopa decarboxylase (Ddc) and sub-
units of the glycine receptor (Glra2, Glrb ; Table 1a). In
contrast, four validated genes of the 29, including b
bradykinin receptor (Bdkrb1) and the NMDA2B iono-
tropic glutamate receptor (Grin2b), were up-regulated
(Table 1b). All genes selected for the validation of en-
dotoxin treatment were signiﬁcantly up-regulated in
the real-time PCR assay (Table 2).
Discussion
According to the current view, major depressive dis-
order and bipolar disorder are caused by plastic
alterations of distributed networks involving multiple
neurotransmitters and pathways (Stone et al. 2008).
There is still much controversy concerning the changes
in the brain that underlie the therapeutic actions of
antidepressants and mood stabilizers. Moreover, de-
spite the emerging knowledge of the pathophysiology
of mood disorders, a relatively high proportion of
patients do not respond to existing medications
(Martinowich et al. 2009; Sanacora et al. 2008), which
urges the discovery and validation of new potential
therapeutic targets. One such target could be the
P2rx7s. Therefore, we tested this hypothesis by the
evaluation of the genetic deletion and pharmacologi-
cal antagonism of P2rx7s in several behavioural
paradigms used for testing antidepressants and mood-
stabilizing drugs. P2rx7x/x mice did not develop
behavioural despair in the FST and reduced immo-
bility was detected in the TST. In addition, we report
here for the ﬁrst time an attenuated response of
P2rx7x/xmice in the AH test, a widely used model of
the manic pole of bipolar disorder. Because there was
no diﬀerence between the two genotypes in the OF
and EPM tests, the observed changes in behaviour
could not be accounted for by changes in spontaneous
locomotor activity or anxiety. These observations
conﬁrm and extend previous data, which showed de-
creased immobility in the TST (Basso et al. 2009) and
decreased ﬂoating time in the FST on the second day
(Boucher et al. 2011) after genetic deletion. However,
partly diﬀering from the study of Basso et al., in our
experiments there was no signiﬁcant diﬀerence in the
basal immobility in the FST between the two geno-
types, which might be explained by diﬀerent housing
conditions and purely homozygous mouse strain of a
diﬀerent origin used by the above study.
Changes in behaviour were accompanied by corre-
sponding alterations in brain monoamine levels in the
amygdala and the striatum of P2rx7x/x mice. In line
with the decreased behavioural despair in the FST and
decreased immobility in the TST, an increase in basal
norepinephrine level was found in the amygdala,
which could be reproduced by P2rx7 antagonist
treatment. As a neurochemical correlate of decreased
hyperlocomotion, amphetamine-induced elevation of
dopamine content and release in the striatum were
also alleviated in P2rx7x/x mice.
P2rx7x/x mice responded with a decreased elev-
ation of plasma ACTH and corticosterone in response
to restraint stress, which suggests that P2rx7x/x mice
react with an attenuated response to external stress,
the opposite of what is found in depressive patients.
Functional P2rx7s are expressed on pituitary cells
(Chung et al. 2000), which, together with our in vitro
results, suggests a direct ATP eﬀect on ACTH se-
cretion. Nevertheless, an indirect action through other
neuronal pathways converging on the hypothalamic–
pituitary–adrenal axis cannot be excluded either.
Interestingly, norepinephrine, dopamine and 5-HT
levels were higher in the amygdala of P2rx7x/x mice
after restraint, which indicates an interaction between
stress and the brain monoaminergic system, which is
regulated by P2rx7.
Importantly, we could reproduce the eﬀect of gen-
etic deletion by the systemic application of a speciﬁc
antagonist of P2rx7s. BBG is a non-toxic and fairly
selective antagonist of P2rx7s, which is able to pen-
etrate the blood–brain barrier (Peng et al. 2009).
Although it was active only using a sub-acute appli-
cation, BBG dose-dependently decreased immobility
antidepressant, decreased basal immobility in the TST in P2rx7+/+mice (n=11/group, * p<0.05 vs. Sal, Student’s t test). (d) Eﬀect
of 1-wk daily treatment with BBG (25–50 mg/kg i.p.) or Sal on amphetamine induced hyperactivity in P2rx7+/+mice.
(n=10–12/group, ** p<0.001 vs. Sal, one-way ANOVA followed by Dunnett’s test). Citalopram and BBG were administered
i.p. 30 min before testing at the doses (mg/kg) indicated on the abscissa. Sal-treated mice were injected with an equal volume
of Sal. (e) Eﬀect of sub-acute, 1-wk treatment with BBG (50 mg/kg i.p.) on basal immobility in P2rx7x/x mice. Mice
were treated with BBG for 7 d or with Sal and then submitted to the TST (n=8–10/group). (f) Eﬀect of 1-wk daily treatment
with BBG (50 mg/kg i.p.) or Sal on amphetamine-induced hyperactivity in P2rx7x/x mice (n=10/group). Note that the basal
immobility (e) and amphetamine-induced hyperactivity (f) is lower in Sal-treated P2rx7x/x mice than in Sal-treated P2rx7+/+
mice. (g) Sub-acute, 1-wk treatment with BBG (50 mg/kg i.p.) elevates NE, but not 5-HT levels in the amygdala in P2rx7+/+mice,
when compared to Sal-treated mice. Tissue content of NE and 5-HT were analysed by high performance liquid chromatography
and are expressed in pmol/mg protein, n=11–12, ** p<0.01, Student’s t test.
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Fig. 5. Mood-stabilizing phenotype is not detectable in chimeric mice transplanted with the bone marrow of P2rx7x/x mice.
(a) General scheme of bone marrow transplantation. (b) Flow cytometric analysis of the expression of the donor-speciﬁc
CD45.2 allele on peripheral blood granulocytes of an intact C57BL/6J mouse (donor), a CD45.1-expressing congenic mouse
(recipient) and bone marrow chimeras engrafted with P2rx7+/+ and P2rx7x/x bone marrow cells (P2rx7+/+ and P2rx7x/x
chimeras, respectively). (c–f) Immunocytochemical demonstration of the P2rx7 in mouse microglial cells. Co-localization of
P2rx7s (labelled red) with microglial labelling CD11b (green) was found in microglia cells retrieved from P2rx7+/+ mouse
brain tissue (c) and in chimeras transplanted with P2rx7+/+ bone marrow [(e) CD45.1/ P2rx7+/+]. Microglial cells of
P2rx7x/x animals (d) did not show P2rx7 immunoreactivity. In chimeras transplanted with P2rx7x/x bone marrow [(f),
CD45.1/P2rx7x/x], the P2rx7 (labelled red) was not found on microglial cells (labelled green) but was in some unidentiﬁed
cells and cell debris in the cell suspension/fraction. Electron microscopy supported this ﬁnding. The cell membrane of
morphologically characterized microglial cells – dark nuclei, either oval or bean shaped, electron dense cytoplasm,
long cisternae of granular endoplasmic reticulum and large inclusions of phagocytosed material in the cell bodies that
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in the TST and attenuated hyperactivity elicited by
amphetamine in P2rx7+/+ mice. Consistent with the
involvement of P2rx7 in these eﬀects, an identical BBG
treatment was ineﬀective in both tests in P2rx7x/x
mice.
Recent studies have shown that certain behavioural
patterns, such as pathological grooming, can be
transferred from one animal to another by immune
cell transplantation (Chen et al. 2010). Circulating
cytokines, including IL-1b, are important mediators
of depressive-like behaviour (Dantzer et al. 2008) and,
therefore, peripheral IL-1b could be a mediator of
P2rx7 activation on mood-related changes. In bone
marrow chimera mice transplanted with the P2rx7x/x
bone marrow, the changes in behaviour in the TST and
AH could not be reproduced despite the >99% re-
constitution of donor cells among recipient leukocytes.
These data suggest that the lack of P2rx7 expressed
on peripheral immune cells is not responsible for
the behavioural phenotype found in P2rx7x/x mice.
The majority of brain microglial cells derived from
P2rx7x/x/CD45.1 mice were negative for the P2rx7,
are commonly found in old animals – were covered by diaminobenzidine precipitates, demonstrating P2rx7
immunoreactivity (c and e rows). Cell processes of unidentiﬁed cells also showed P2rx7 immunoreactivity (e). Microglial
cells of P2rx7 gene knockout animals (d) or microglial cells from CD45.1/P2rx7x/x animals (f) were free of precipitate.
(g, h) Basal immobility time in the tail suspension test (g) and amphetamine-induced hyperactivity (h) were not diﬀerent
in CD45.1/P2rx7+/+ and CD45.1/P2rx7x/x mice. Mice were submitted to behaviour tests 8 wk after engraftment
(n=13–14/group).
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represents three transcripts, which were not only signiﬁcantly aﬀected by LPS treatment but may also be altered by genotype,
whereas the intersection of the blue and green circles represents one transcript, which is not only signiﬁcantly aﬀected by
knockout genotype but may also be altered by LPS treatment. (b) Deﬁciency of the P2rx7 had the most profound eﬀect on the
expression proﬁle, changing the expression of 8448 transcripts. Among them, 3133 were increased (red) and 5315 were decreased
(blue), as illustrated by the deviation of the lines according to the normalized intensity values.
P2X7 receptor and mood-related behaviour 225
Table 1. Genes that were up- and down-regulated by the deﬁciency of P2rx7 in the mouse amygdala
Symbol Gene ID Gene name (accession number)
Agilent
(FC)
Real-time
PCR (RQ) TaqMan ID
(a)
Adra2a 11 551 Adrenergic receptor a2a (NM_007417) 2.72 1.34¡0.38
p=0.0171
Mm00845383_s1
Adrb1 11 554 Adrenergic receptor b1 (NM_007419) 4.77 Mm00431701_s1
Ak5 229 949 Adenylate kinase 5 (NM_001081277) 5.71 Mm00461978_m1
Aplp2 11 804 Amyloid b (A4) precursor-like protein 2
(NM_009691)
5.55 Mm00507819_m1
Bdnf 12 064 Brain derived neurotrophic factor isoform 1
(NM_007540)
3.89 Mm01334047_m1
Casp8 12 370 Caspase 8 (NM_009812) 9.57 Mm00802247_m1
Chkb 12 651 Choline kinase b (NM_007692) 4.160 Mm00432498_m1
Cnr1 12 801 Cannabinoid receptor 1 (NM_007726) 2.081 1.31¡0.28
p=0.0087
Mm01212171_s1
Ddc 13 195 Dopa decarboxylase (NM_016672) 2.051 1.58¡0.84
p=0.0249
Mm00516688_m1
Drd2 13 489 Dopamine receptor 2 (NM_010077) 2.37 2.44¡0.47
p=0.0120
Mm00438545_m1
Gabarapl1 57 436 GABAA receptor-associated protein-like 1
(NM_020590)
4.47 Mm00457880_m1
Gabra1 14 394 GABAA receptor subunit a1 (NM_010250) 4.130 Mm00439046_m1
Gabra5 110 886 GABAA receptor subunit a5 (NM_176942) 7.79 Mm00621092_m1
Gabrb2 14 401 GABAA receptor subunit b2 (NM_008070) 2.141 2.51¡1.12
p=0.0036
Mm00549788_s1
Gabrb3 14 402 GABAA receptor subunit b3 (NM_008071) 2.041 1.34¡0.55
p<0.0005
Mm00433473_m1
Gabrg1 14 405 GABAA receptor subunit c1 (NM_010252) 2.55 3.38¡1.19
p=0.0005
Mm00439047_m1
Gabrg2 14 406 GABAA receptor subunit c2 (NM_008073) 2.43 2.04¡0.89
p=0.0012
Mm00433489_m1
Gad1 14 415 Glutamic acid decarboxylase 1 (NM_008077) 2.171 1.10¡0.06
p=0.0009
Mm00725661_s1
Gfra1 14 585 Glial cell line derived neurotrophic factor
family receptor a1 (NM_010279)
2.231 1.82¡0.54
p=0.0308
Mm00833897_m1
Gja1 14 609 Gap junction protein a1 (NM_010288) 4.097 Mm00621092_m1
Gjb6 14 623 Gap junction protein b6 (NM_001010937) 4.48 1.40¡0.28
p<0.0016
Mm00433661_s1
Gjc1 14 615 Gap junction protein c1 (NM_008122) 2.161 1.247¡0.11
p=0.0050
Mm01253027_m1
Gjd2 14 617 Gap junction protein d2 (NM_010290) 4.61 Mm00439121_m1
Gje1 76 743 Gap junction membrane channel protein e1
(NM_080450)
2.00 1.49¡0.18
p=0.0022
Mm00519120_s1
Glra2 237 213 Glycine receptor a2 subunit (NM_183427) 2.34 1.30¡0.25
p=0.0157
Mm00439140_m1
Glrb 14 658 Glycine receptor b subunit (NM_010298) 5.089 1.16¡0.25
p=0.0018
Mm00439140_m1
Gria2 14 800 Glutamate receptor, ionotropic, AMPA2 (a2) 2.59 1.13¡0.05
p<0.0002
Mm00442822_m1
Gria4 14 802 Glutamate receptor, ionotropic, AMPA4 (a4),
transcript variant 1 (NM_019691)
2.74 1.41¡0.66
p=0.0014
Mm00444754_m1
Grm7 108 073 Glutamate receptor, metabotropic 7
(NM_177328)
35.81 1.07¡0.16
p=0.0317
Mm01189424_m1
Gstm4 14 865 Glutathione S-transferase m4 (NM_026764) 3.34 Mm00728197_s1
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Table 1 (cont.)
Symbol Gene ID Gene name (accession number)
Agilent
(FC)
Real-time
PCR (RQ) TaqMan ID
Klhl12 240 756 Kelch-like 12 (Drosophila) (NM_153128) 6.98 1.19¡0.31
p=0.0074
Mm00462323_m1
Narg1l 66 897 NMDA receptor regulated 1-like (NM_025832) 6.98 1.77¡0.21
p=0.0032
Mm00462323_m1
Ncam1 17 967 Neural cell adhesion molecule 1 (NM_010875) 3.310 Mm00456815_m1
Npy5r 18 168 Neuropeptide Y receptor Y5 (NM_016708) 6.68 Mm02620267_s1
P2ry1 18 441 Purinergic receptor P2Y, G-protein coupled 1
(NM_008772)
3.89 1.47¡0.73
p=0.0467
Mm00435471_m1
Pcdh10 18 526 Protocadherin 10 (NM_001098171) 14.93 Mm00477987_s1
Pcmt1 18 537 Protein-L-isoaspartate (D-aspartate)
O-methyltransferase 1 (NM_008786)
2.251 1.23¡0.28
p=0.0073
Mm00476600_m1
Pde1a 18 573 Phosphodiesterase 1A calmodulin-
dependent (NM_016744)
2.191 1.24¡0.74
p=0.0123
Mm00450244_m1
Plp1 18 823 Proteolipid protein (myelin) 1 (NM_011123) 9.031 1.51¡0.18
p=0.0033
Mm00456892_m1
Ryr3 20 192 Ryanodine receptor 3 (BC116740) 2.80 1.79¡0.22
p<0.0002
Mm01335482_m1
(b)
Adcy8 11 514 Adenylate cyclase (NM_009623) 17.56 Mm00507722_m1
Adrbk1 110 355 Adrenergic receptor kinase b1 (NM_130863) 5.55 Mm00804778_m1
Adrbk2 320 129 Adrenergic receptor kinase b2 (NM_177080) 4.38 Mm00622037_m1
Aloxe3 23 801 Arachidonate lipoxygenase 3 (NM_011786) 5.121 Mm004778628_m1
Anxa7 11 750 Annexin A7 (NM_009674) 3.94 Mm00477549_m1
Avp 11 998 Arginin vasopressine (NM_009732) 57.00 Mm00437761_g1
Bai1 107 831 Brain-speciﬁc angiogenesis inhibitor 1
(NM_174991)
2.52 Mm00558144_m1
Bdrkb1 12 061 Bradykinin receptor b1 (NM_007539) 27.79 1.60¡0.43
p=0.0498
Mm00432059_s1
Crhr2 12 922 Corticotropin releasing hormone receptor 2
(NM_007539)
5.110 5.89¡0.43
p=0.0040
Mm00438303_m1
Drd4 13 491 Dopamine receptor 4 (NM_007878) 4.580 Mm004382893_m1
Gabrd 14 403 GABAA receptor subunit delta (NM_008072) 2.72 Mm00433476_m1
Gabrr1 14 408 GABAC receptor, subunit rho (NM_008075) 4.123 Mm00433499_m1
Gcat 26 912 Glycine C-acetyltransferase (2-amino-3
ketobutyrate-coenzyme A ligase)
(NM_013847)
25.45 Mm00496962_m1
Glul 14 645 glutamate-ammonia ligase (glutamine
synthetase) (NM_008131)
4.56 Mm00725701_s1
Grik1 14 805 Glutamate receptor, ionotropic, kainate 2
(NM_010348)
12.130 Mm00446882_m1
Grik5 14 809 Glutamate receptor, ionotropic, kainate 5
(c2) (NM_008168)
9.95 Mm00435701_m1
Grin2b 14 812 Glutamate receptor, ionotropic, NMDA2B
(e2) (NM_008171)
2.77 1.10¡0.13
p=0.0062
Mm00433820_m1
Grin2d 14 814 Glutamate receptor, ionotropic, NMDA2D
(e4) (NM_008171)
7.168 Mm00433822_m1
Grm1 14 816 Glutamate receptor metabotropic 1
(NM_016976)
33.64 Mm00810231_s1
Grm5 108 071 Glutamate receptor metabotropic 5
(NM_001081414)
6.110 Mm00690332_m1
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which implies that the observed changes of mood-
related behaviour were also independent from micro-
glial P2rx7s that might regulate IL-1b production
(Sperlagh & Illes, 2007b). Moreover, the basal IL-1b
level was not subject to regulation by P2rx7, either in
the amygdala (present study) or in the serum and
hippocampus (Cso¨lle & Sperla´gh, 2010), which is
against the role of IL-1b as a mediator of behavioural
changes shown here.
Consequently, P2rx7s expressed on other cell types,
most likely on neurons or astrocytes, are responsible
for P2rx7-related changes in mood. Our ﬁndings
also indicated P2rx7-dependent changes in mono-
amine levels in the amygdala, which is an intrinsic
part of the neuronal circuitry regulating emotions and
the site of action of antidepressants (Castro et al. 2010).
Moreover, a recent study (Boucher et al. 2011) showed
that c-Fos expression induced by a repeated FST in
the amygdala was attenuated by the genetic deletion
of P2rx7. Therefore, to gain insight into the impact
of P2rx7s on gene expression in this region, a whole
genome microarray analysis was performed. Here we
should note that the amygdala is a heterogeneous
brain nucleus, comprising anatomically and function-
ally distinct subnuclei. Among them, the basolateral
amygdala has primarily been associated with
emotional processing, whereas our analyses were
performed on the whole amygdala. Our data show
that the expression of a surprisingly high number of
genes (>8000) was changed signiﬁcantly by genetic
deletion of P2rx7, which is in line with the results of
Boucher et al. (2011), who found a relatively selective
decrease of c-Fos activation in the basolateral amyg-
dala of P2rx7x/x mice after repeated FST. Twenty-
nine out of the 60 genes selected for validation were
signiﬁcantly down- or up-regulated in the real-time
PCR assay. The majority of these genes have biological
plausibility in synaptic signalling and neuroplasticity
and could be linked to the pathogenesis of depression.
Interestingly, a down-regulation of the dopa de-
carboxylase enzyme was found in the absence of
P2rx7, which indicates that elevated norepinephrine
levels in the amygdala are not due to increased syn-
thesis but decreased metabolism or utilization. In ad-
dition, D2 receptors were also down-regulated in
the amygdala of P2rx7x/x mice. Consistent with the
presumed dysfunction of glutamatergic transmission
and consequent neuroplasticity changes in depression
(Sanacora, 2010 ; Sanacora et al. 2008), a down-
regulation of diﬀerent a-amino-3-hydroxyl-5-methyl-
4-isoxazole-propionate (AMPA) and metabotropic
glutamate receptor subunits (Gria 2, Gria 4, Grm 7) and
the glial cell-derived neurotrophic factor was detected
in P2rx7x/x mice. In contrast, an up-regulation of
the NR2B subunit of N-methyl-D-aspartate receptors
(Grin2b) and CRHR2 receptors (crhr2) were found
in P2rx7x/x mice. These changes in gene expression
proﬁle might also underlie the behavioural alterations
and decreased stress reactivity found in the absence of
P2rx7. Genes related to GABAergic transmission were
Table 1 (cont.)
Symbol Gene ID Gene name (accession number)
Agilent
(FC)
Real-time
PCR (RQ) TaqMan ID
Nrxn2 18 190 Neurexin II (NM_020253) 7.131 1.28¡0.18
p<0.0328
Mm01236851_m1
P2rx2 231 602 Purinergic receptor P2X, ligand-gated
ion channel, 2 (NM_153400)
11.180 Mm00462952_m1
GABA, c-aminobutyric acid ; NMDA, N-Methyl-D-aspartate.
The table shows the comparison of gene expression data frommicroarray and real-time polymerase chain reaction (PCR) studies.
The detected changes in the expression level are expressed in fold change (FC) in the microarray study and relative quantity
(RQ) in the PCR study. Among the representative list of 60 genes of interest, 39 were down-regulated (a) and 21 were up
regulated (b) exclusively by P2rx7 deletion in the mouse amygdala using the selection ﬁlters of>2.0-FC in the microarray study.
Signiﬁcant diﬀerences were calculated by a two-way analysis of variance (ANOVA) followed by Benjamini–Hochberg’s multiple
correction, with p<0.05. Signiﬁcant down- or up-regulatory eﬀects of P2rx7 deﬁciency were conﬁrmed for 29 of the genes by
TaqMan-based quantitative real-time PCR (TLDA). Samples of RNA from the microarray experiment (n=4) and from an in-
dependent experiment (n=4) were measured for each group on TLDA and the results were evaluated by RealTime StatMiner
software. (a) Twenty-ﬁve genes among the total of 39 were changed signiﬁcantly (two-way ANOVA, p<0.05) and showed
similarity in size and direction by both methods. (b) Four out of 21 genes were changed signiﬁcantly (two-way ANOVA, p<0.05)
and showed similarity in size and direction by both methods. The TaqMan ID gives the product number of Applied Biosystems
Gene Expression Assay used for the validation of the corresponding gene.
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also aﬀected by genetic deletion, causing a subtype-
speciﬁc up- and down-regulation of various GABAA
receptor subunits and the down-regulation of the
GABA synthesizing enzyme, glutamic acid decarboxy-
lase. These changes are consistent with previous
results showing that the activation of P2rx7s in the
brain leads to an increased glutamate and GABA re-
lease from nerve terminals (Papp et al. 2004; Patti et al.
2006; Sperlagh et al. 2002) and astrocytes (Duan et al.
2003). Therefore, it is tempting to speculate that the
Table 2. Genes that were up-regulated by lipopolysaccharide (LPS) treatment in the mouse amygdala
Symbol Gene ID Gene name (accession number)
Agilent
(FC)
Real-time
PCR (RQ) TaqMan ID
Iﬁt1 15 957 Interferon-induced protein with tetratricopeptide repeats 1
(NM_008331)
>1000 25.77 Mm00515153_m1
p<0.0001
Casp4 12 363 Caspase 4, apoptosis-related cysteine peptidase (NM_007609) >1000 19.24 Mm00432307_m1
p=0.0007
Ccl5 20 340 Chemokine (C—C motif) ligand 5 (NM_013653) >1000 745.12 Mm01302428_m1
p=0.0002
Ccl9 20 308 Chemokine (C—C motif) ligand 9 (NM_011338) >1000 20.22 Mm00441260_m1
p=0.0001
Cxcl10 15 945 Chemokine (C—X—C motif) ligand 10 (NM_021274) >1000 518.39 Mm99999072_m1
p=0.0002
Cxcl16 66 102 Chemokine (C—X—C motif) ligand 16 (NM_023158) 55.71 7.94 Mm00469712_m1
p=0.0007
Gbp2 14 469 Guanylate nucleotide binding protein 2 (NM_010260) >1000 68.13 Mm00494575_m1
p=0.0001
Gpr65 14 744 G-protein coupled receptor 65 (NM_008152) >1000 10.44 Mm02619732_s1
p=0.0021
Igtp 16 145 Interferon c induced GTPase (NM_018738) >1000 10.43 Mm00497611_m1
p=0.0002
Iigp1 60 440 Interferon inducible GTPase 1 (NM_021792) >1000 46.86 Mm00649928_s1
p=0.0001
Il1rn 16 181 Interleukin 1 receptor antagonist (NM_001039701) >1000 >1000 Mm01337566_m1
p=0.0001
Il4ra 16 190 Interleukin 4 receptor, a (NM_001008700) 23.58 6.81 Mm00439634_m1
p<0.0001
Irgm 15 944 Immunity-related GTPase family (NM_008326) >1000 21.93 Mm00492596_m1
p=0.0024
Isg20 57 444 Interferon- stimulated protein (NM_020583) >1000 12.29 Mm00469585_m1
p=0.0001
Mpa2l 100 702 Macrophage activation 2 like (NM_194336) >1000 61.41 Mm00843395_m1
p=0.0001
Saa1 20 208 Serum amyloid A 1 (NM_009117) >1000 34.91 Mm00656927_g1
p=0.0026
Tlr2 24 088 Toll like receptor 2 (NM_0119057) >1000 36.57 Mm00442346_m1
p=0.0004
The table shows the comparison of gene expression data frommicroarray and real-time polymerase chain reaction (PCR) studies.
Seventeen genes were selected among the exclusively up-regulated genes by systemic LPS (250 mg/kg i.p.) in the mouse
amygdala (P2rx7+/+ and P2rx7x/x) using the selection ﬁlters of>2.0-fold change (FC) in the microarray study. Signiﬁcant
diﬀerences were calculated by two-way analysis of variance (ANOVA) followed by Benjamini–Hochberg’s multiple correction,
with p<0.05. These changes were validated by TaqMan-based quantitative real-time PCR (TLDA). The detected changes in the
expression level are expressed in FC in the microarray study and relative quantity (RQ) in the PCR study. The change of all 17
genes was statistically signiﬁcant (two-way ANOVA, p<0.05) and showed similarity in direction by both methods. Samples of
RNA from the microarray experiment (n=4) and from an independent experiment (n=4) were measured for each group on
TLDA and the results were evaluated by RealTime StatMiner software. The TaqMan ID gives the product number of Applied
Biosystems Gene Expression Assay used for the validation of the corresponding gene.
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increased activation due to gain-of-function mutations
of the P2RX7 gene (Stokes et al. 2010) may lead to
glutamatergic over-activation. This over-activation
would lead to depressive symptoms, whereas the lack
of these eﬀects in the absence of the P2rx7 results in
compensatory changes in the expression of glutamate
and GABA receptors. This assumption is strengthened
by observations from animal and human studies, in-
dicating that excessive glutamate transmission might
be involved in the pathophysiology of depressive
disorders. These include abnormalities in the level
of glutamate (Hashimoto et al. 2007), genetic poly-
morphisms (Mundo et al. 2003), the diﬀerential ex-
pression of glutamate receptor subunits in bipolar
and major depressive disorders (Meador-Woodruﬀ
et al. 2001; Toro & Deakin, 2005), the antidepressant
properties of glutamate receptor antagonists and
modulators (Sanacora et al. 2008) and the regulation of
glutamate receptor subunits by clinically used anti-
depressants (Nowak et al. 1998; Skolnick et al. 1996).
As a control stimulus, gene expression changes
were also examined after a relatively modest LPS
stimulus. This treatment elicited the signiﬁcant change
of 570 transcripts with>2FC, which is comparable to
the gene expression changes found by others in the
brain after systemic endotoxin treatment (Marques
et al. 2009; Marsh et al. 2009; Mastronardi et al. 2007;
Perreau et al. 2007). Therefore, genes encoding
chemokines and other signalling proteins of immune
response were primarily up-regulated by the endo-
toxin.
In conclusion, our data show that the genetic de-
letion and pharmacological antagonism of P2rx7s
leads to selective alteration in mood-related behaviour
and related changes in brain monoamine levels, stress
reactivity and gene expression. Although the precise
translation of P2rx7 function to behavioural changes
needs further investigation, our data may open up
new avenues in the treatment of mood disorders.
Note
Supplementary material accompanies this paper on
the Journal’s website (http://journals.cambridge.org/
pnp).
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